Cefepime clinical studies: Difference between revisions
Jump to navigation
Jump to search
(Created page with "Febrile Neutropenic Patients The safety and efficacy of empiric cefepime monotherapy of febrile neutropenic patients have been assessed in two multicenter, randomized trials ...") |
No edit summary |
||
| Line 1: | Line 1: | ||
Febrile Neutropenic Patients | ===Febrile Neutropenic Patients=== | ||
The safety and efficacy of empiric cefepime monotherapy of febrile neutropenic patients have been assessed in two multicenter, randomized trials comparing cefepime monotherapy (at a dose of 2 g intravenously every 8 hours) to ceftazidime monotherapy (at a dose of 2 g intravenously every 8 hours). These studies comprised 317 evaluable patients. | The safety and efficacy of empiric cefepime monotherapy of febrile neutropenic patients have been assessed in two multicenter, randomized trials comparing cefepime monotherapy (at a dose of 2 g intravenously every 8 hours) to ceftazidime monotherapy (at a dose of 2 g intravenously every 8 hours). These studies comprised 317 evaluable patients. | ||
| Line 65: | Line 65: | ||
|} | |} | ||
<SMALL>ANC = absolute neutrophil count; SBP = systolic blood pressure</SMALL> | |||
Revision as of 14:53, 20 December 2013
Febrile Neutropenic Patients
The safety and efficacy of empiric cefepime monotherapy of febrile neutropenic patients have been assessed in two multicenter, randomized trials comparing cefepime monotherapy (at a dose of 2 g intravenously every 8 hours) to ceftazidime monotherapy (at a dose of 2 g intravenously every 8 hours). These studies comprised 317 evaluable patients.
| Total | Cefepime | Ceftazidime |
| 164 | 153 | |
| Median age (yr) | 56 (range, 18 to 82) | 55 (range, 16 to 84) |
| Male | 86 (52%) | 85 (56%) |
| Female | 78 (48%) | 68 (44%) |
| Leukemia | 65 (40%) | 52 (34%) |
| Other hematologic malignancies | 43 (26%) | 36 (24%) |
| Solid tumor | 54 (33%) | 56 (37%) |
| Median ANC nadir (cells/microliter) | 20 (range, 0 to 500) | 20 (range, 0 to 500) |
| Median duration of neutropenia (days) | 6 (range, 0 to 39) | 6 (range, 0 to 32) |
| Indwelling venous catheter | 97 (59%) | 86 (56%) |
| Prophylactic antibiotics | 62 (38%) | 64 (42%) |
| Bone marrow graft | 9 (5%) | 7 (5%) |
| SBP less than 90 mm Hg at entry | 7 (4%) | 2 (1%) |
ANC = absolute neutrophil count; SBP = systolic blood pressure